Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
|Articles|April 27, 2023
Talking Automation in Fill/Finish and Cell & Gene Therapies with James Rorke (INTERPHEX 2023)
James Rorke, vice-president, operations, Steriline North America, discusses the benefits of automation in fill/finish operations.
Advertisement
James Rorke, vice-president, operations, Steriline North America, discusses the advantages of automation in fill/finish, particulary for low volume, high quaility products such as cell and gene therapies, for which minimizing product loss is crucial.
For more INTERPHEX 2023 video content, check
Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
Emily Heffernan, director of new process technologies at Arcadis, explains what it takes to design a facility that can produce both lentiviral vectors and mRNA-LNPs, and how in vivo platforms change QC release testing.
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Cemiplimab's proposed EU regimen could cut Libtayo infusion visits from every 3 weeks to every 6 weeks, trimming infusion time by up to half.
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
3
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
4
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
5